Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
Status:
Recruiting
Trial end date:
2022-06-06
Target enrollment:
Participant gender:
Summary
This is a Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled
study designed to investigate the potential effect of tezepelumab (210 mg subcutaneous [SC]
every 4 weeks [Q4W]) on antibody responses following seasonal quadrivalent influenza virus
vaccination in the fall/winter 2021-2022 in the USA.